ALNY
Price:
$242.26
Market Cap:
$31.25B
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1)...[Read more]
Industry
Biotechnology
IPO Date
2004-06-01
Stock Exchange
NASDAQ
Ticker
ALNY
According to Alnylam Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 31.45B. This represents a change of 9.01% compared to the average of 28.85B of the last 4 quarters.
The mean historical Enterprise Value of Alnylam Pharmaceuticals, Inc. over the last ten years is 13.67B. The current 31.45B Enterprise Value has changed 22.91% with respect to the historical average. Over the past ten years (40 quarters), ALNY's Enterprise Value was at its highest in in the September 2024 quarter at 35.57B. The Enterprise Value was at its lowest in in the December 2016 quarter at 3.17B.
Average
13.67B
Median
11.62B
Minimum
3.16B
Maximum
29.37B
Discovering the peaks and valleys of Alnylam Pharmaceuticals, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 244.49%
Maximum Annual Enterprise Value = 29.37B
Minimum Annual Increase = -52.29%
Minimum Annual Enterprise Value = 3.16B
Year | Enterprise Value | Change |
---|---|---|
2023 | 25.78B | -12.24% |
2022 | 29.37B | 44.95% |
2021 | 20.26B | 35.37% |
2020 | 14.97B | 21.30% |
2019 | 12.34B | 77.72% |
2018 | 6.94B | -36.23% |
2017 | 10.89B | 244.49% |
2016 | 3.16B | -52.29% |
2015 | 6.63B | 4.79% |
2014 | 6.32B | 61.94% |
The current Enterprise Value of Alnylam Pharmaceuticals, Inc. (ALNY) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
25.14B
5-year avg
20.55B
10-year avg
13.67B
Alnylam Pharmaceuticals, Inc.’s Enterprise Value is greater than ProQR Therapeutics N.V. (192.74M), greater than Wave Life Sciences Ltd. (1.72B), greater than Blueprint Medicines Corporation (6.12B), greater than Apellis Pharmaceuticals, Inc. (4.20B), greater than Incyte Corporation (12.19B), greater than United Therapeutics Corporation (15.08B), greater than Ultragenyx Pharmaceutical Inc. (3.93B), greater than BioMarin Pharmaceutical Inc. (12.56B), less than Seagen Inc. (42.84B), greater than Exelixis, Inc. (9.50B), greater than Halozyme Therapeutics, Inc. (7.35B), greater than Krystal Biotech, Inc. (4.25B), greater than Madrigal Pharmaceuticals, Inc. (6.67B), greater than Reata Pharmaceuticals, Inc. (6.64B), greater than IVERIC bio, Inc. (5.13B), greater than Amylyx Pharmaceuticals, Inc. (209.72M), greater than Karuna Therapeutics, Inc. (12.43B), greater than Day One Biopharmaceuticals, Inc. (859.59M),
Company | Enterprise Value | Market cap |
---|---|---|
192.74M | $275.55M | |
1.72B | $2.00B | |
6.12B | $5.74B | |
4.20B | $4.13B | |
12.19B | $13.45B | |
15.08B | $16.23B | |
3.93B | $4.05B | |
12.56B | $12.63B | |
42.84B | $43.15B | |
9.50B | $9.56B | |
7.35B | $6.00B | |
4.25B | $4.63B | |
6.67B | $6.78B | |
6.64B | $6.57B | |
5.13B | $5.51B | |
209.72M | $278.99M | |
12.43B | $12.60B | |
859.59M | $1.28B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Alnylam Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Alnylam Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is Alnylam Pharmaceuticals, Inc.'s Enterprise Value?
What is the highest Enterprise Value for Alnylam Pharmaceuticals, Inc. (ALNY)?
What is the 3-year average Enterprise Value for Alnylam Pharmaceuticals, Inc. (ALNY)?
What is the 5-year average Enterprise Value for Alnylam Pharmaceuticals, Inc. (ALNY)?
How does the current Enterprise Value for Alnylam Pharmaceuticals, Inc. (ALNY) compare to its historical average?